Mustafa Değirmenci

Mustafa Değirmenci

Auto-generated profile, based on publicly available information

Mustafa Değirmenci

Department of Medical Oncology, Izmir City Hospital, Izmir 35540, Türkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DMDegirmenci Mustafa
Degirmenci Mustafa
BIBulduk Ibrahim
Bulduk Ibrahim
AEAkbel Erten
Akbel Erten
Pazopanib, which is dangerous for aquatic environments due to its toxic and bioaccumulation potential, has been detected at different concentrations in oncology hospital wastewater, sewage, and surface waters. This study aimed to remove pazopanib from wastewater by activated carbon adsorption technique. The effect of the main variables such as initial concentration, pH of pazopanib solution, adsorbent dose, contact time of the phases, and temperature on the adsorption process was evaluated and the optimum adsorption conditions were determined. The experimental data were applied to Langmuir, Freundlich, Temkin, and Dubinin-Radushkevich adsorption isotherm models to describe the adsorption behavior. The experimental data were applied to pseudo-first-order, pseudo-second-order, and intra-particle diffusion kinetic models to describe the adsorption kinetics. Isotherms were established in the 20–50 °C temperature range to study the adsorption equilibrium. According to the results, the highest removal efficiency of pazopanib (95.87%) was obtained at initial concentration (100 mg L−1), adsorbent dose (0.30 g L−1), temperature (20 °C), contact time (120 min) and pH (7.0). The adsorption kinetics was well described by the pseudo-second-order kinetic model (R2 = 0.9998) and the adsorption isotherm by the Langmuir model (R2 = 0.9999). In thermodynamic studies, the negative values of standard enthalpy (ΔH°), standard free enthalpy (ΔG°), and free entropy (ΔS°) indicate that the adsorption process is spontaneous and favorable, i.e. the disorder is reduced. These results indicate that the developed adsorption process can be efficiently and spontaneously applied for the removal of pazopanib from aqueous solutions.

1 January 2024 in European Journal of Breast Health
Verified
Journal Article
Closed access
CKCem Karaali
Cem Karaali
MEMümin Emiroğlu
Mümin Emiroğlu
MDMustafa Değirmenci
Mustafa Değirmenci
MKMurat Keser
Murat Keser
SSSemra Salimoğlu
Semra Salimoğlu
ETEsra Canan Kelten Talu
Esra Canan Kelten Talu
Estrogen receptor (ER) expression is an immunohistochemical marker that is examined in all invasive breast cancers and has prognostic and predictive value. ER-positive breast cancers refer to those that show positivity for ER at 1% cellular expression or higher. The American Society of Clinical Oncology/College of American Pathologists guidelines suggest using the term “low ER-positive breast cancer” for tumors with ER expression between 1% and 10%. Low ER-positive breast cancers exhibit similarities, in terms of disease-free survival and overall survival rates, to triple-negative breast cancers (TNBCs) rather than ER-positive breast cancers. In this study, our aim was to compare the clinicopathological characteristics of low ER-positive breast cancer cases diagnosed and followed in our clinic with TNBCs. A total of 26 cases of low ER-positive breast cancer diagnosed at University of Health Sciences Turkey, İzmir Tepecik Training and Research Hospital between 2010 and 2016 were retrieved from hospital records. The relevant histopathology slides and blocks were retrieved and re-evaluated retrospectively through microscopic examination. Thirteen cases that met the criteria were included in the study. Additionally, a consecutive series of 13 TNBC cases that did not receive neoadjuvant treatment within the same time period were identified. In the low ER-positive group, the presence of tumor necrosis, as well as histological grade, nuclear grade and Ki-67 proliferation index were significantly lower compared to the TNBC group. Ductal carcinoma in situ (DCIS) was significantly more common in the low ER-positive group compared to the TNBC group. There were no significant differences between the two groups in terms of tumor size, histological tumor type, axillary lymph node involvement, tumor margins, peritumoral and intratumoral inflammation, local recurrence, distant metastasis, survival, and other characteristics. Although our study consisted of a small number of cases, some features showed significant differences between low ER-positive breast cancers and TNBCs. Histological and nuclear grades, as well as the presence of a DCIS component, were associated with low ER-positive breast cancer. In contrast, the presence of tumor necrosis, as well as Grade 3 features and a high Ki-67 proliferation index indicated TNBC.

29 July 2020 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
OEOzlem Ercelep
Ozlem Ercelep
DTDeniz Tataroğlu
Deniz Tataroğlu
MÖMelike Özçelik
Melike Özçelik
HSHeves Surmeli
Heves Surmeli
MDMustafa Değirmenci
Mustafa Değirmenci
MGMahmut Gumus
Mahmut Gumus
To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer. Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated. The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months. All 64 patients received a median of 6 (range, 1-12) bevacizumab and 6 (range, 2-12) chemotherapy cycles. The chemotherapy regimens used with bevacizumab were cisplatin and paclitaxel in 31 (48%) and carboplatin and paclitaxel in 33 (52%) patients. The survival in patients treated with bevacizumab and cisplatin plus paclitaxel was better-particularly in patients with no previous cisplatin-based radiosensitizer therapy-than those treated with carboplatin, paclitaxel, and bevacizumab (p=0.023). The bevacizumab dose was 7.5 mg/kg in 30 patients (47%) and 15 mg/kg in 34 patients (53%) every 21 days. No significant difference was reported in the OS and the PFS between the two groups. While the most common all-grades adverse events were nausea, neutropenia, anemia, and peripheral sensory neuropathy, the most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy. Adding bevacizumab to platinum and paclitaxel chemotherapy in a case of metastatic or recurrent cervical cancer is an effective and tolerable treatment for Turkish patients.

26 December 2025 in Genes
Verified
Journal Article
Open access
PDF file
Seval AkaySeval Akay
Seval Akay
TÖTaha Reşid Özdemir
Taha Reşid Özdemir
OKOzge Ozer Kaya
Ozge Ozer Kaya
MDMustafa Degirmenci
Mustafa Degirmenci
OUOlcun umit Unal
Olcun umit Unal
Background: Germline alterations in DNA damage repair (DDR) genes represent a clinically important subset of prostate cancer (PCa), but real-world data from Middle Eastern and Turkish populations remain limited. We evaluated the prevalence and clinicopathologic associations of germline DDR variants in a single-center Turkish cohort. Methods: We retrospectively analyzed 122 men with histologically confirmed PCa who underwent germline multigene panel testing. Variants were classified according to ACMG/ClinVar criteria. Patients were grouped as pathogenic/likely pathogenic (P/LP), variants of uncertain significance (VUS), or variant-negative. Patients were grouped as variant-positive (P/LP or VUS/uncategorized) or clinically actionable variant–negative (benign/likely benign or no variant detected). Group comparisons used t-tests, chi-square or Fisher’s exact tests as appropriate. Results: The median age at diagnosis was 65.2 years (mean 64.6 ± 8.78). Overall, 37 patients (30.3%) carried at least one germline variant, including 12 (9.8%) with P/LP alterations and 24 (19.7%) with VUS; one patient (0.8%) harbored an uncategorized variant. The most frequently affected genes were CHEK2 (n = 8), BRCA1 (n = 6), BRCA2 (n = 6), ATM (n = 5), and APC (n = 4). Variant-positive status increased from 10.8% in ISUP 1–2 to 21.6% in ISUP 3 and 76.0% in ISUP 4–5, although this trend was not statistically significant (p = 0.391). Mean age at diagnosis and the prevalence of metastatic disease did not differ between variant-positive and clinically actionable variant–negative patients (64.2 vs. 65.7 years, p = 0.390; 66.7% vs. 64.6%, p = 0.842). Truncating DDR variants (RAD50, BRCA2, MSH3, NBN, CHEK2, ATM) occurred predominantly in ISUP 4–5 tumors. Conclusions: Germline DDR alterations—most notably in BRCA2, CHEK2, and ATM—were present in a substantial subset of Turkish men with PCa and showed a non-significant trend toward clustering in higher-grade disease. The high prevalence of VUS reflects limited genomic annotation in under-represented populations and underscores the need for longitudinal reinterpretation. These data support the clinical value of incorporating germline DDR testing into risk assessment and familial counseling, while larger cohorts integrating somatic profiling are needed to refine genotype–phenotype associations.

1 September 2024 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
MDMustafa Degirmenci
Mustafa Degirmenci
GDGulden Diniz
Gulden Diniz
DKDudu Solakoglu Kahraman
Dudu Solakoglu Kahraman
MSMustafa Sahbazlar
Mustafa Sahbazlar
LKLokman Koral
Lokman Koral
RURuchan Uslu
Ruchan Uslu
Background: Trastuzumab is commonly utilized in the management of metastatic HER2-positive breast cancer. Our main goal was to examine the clinical outcomes and immune markers of patients who received trastuzumab and chemotherapy treatment. Methods: Between 1995 and 2012, a total of 98 patients diagnosed with metastatic HER2-positive breast cancer were retrospectively analyzed at Ege University Hospital and Tepecik Training and Research Hospital. The clinicopathological characteristics and clinical outcomes of the patients were assessed, and the associations between response rates, survival and the immune profiles of tumor infiltrating lymphocytes were statistically evaluated. Results: The average age of patients at the time of diagnosis was 50.1± 10.3 (ranging from 30 to 79) years. The mean follow-up period for all patients was 97.9± 53.8 months. Among the patients, complete response was observed in 24.5%, partial response in 61.2%, and stable disease in 8.2% of cases. The average progression-free survival was 50.3± 26.9 months (ranging from 1 to 163 months), and the average overall survival was 88.8± 59.4 months (ranging from 12 to 272 months). After analyzing all cases, it was found that patients who were younger (p=0.006), exhibited higher CD3-positivity (p=0.041), presented with higher FOXP3-positivity (p=0.025), showed complete or at least partial response to treatment (p=0.008), and experienced a long-term response to trastuzumab (and chemotherapy) treatment had longer survival (p=0.001). Conclusion: Patients with HER2-positive breast cancer, who initially respond positively to palliative trastuzumab and chemotherapy treatment, can achieve long-term tumor remission lasting for several years.

19 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
MDMustafa Degirmenci
Mustafa Degirmenci
Purpose: This retrospective study has aimed to determine the possible prognostic significance of cereblon (CRBN) expression in gastrointestinal tract tumors. Methods: In this study, cases of gastrointestinal tract tumors including neuroendocrine tumors (n:38), gastric adenocarcinomas (n:152) and colorectal carcinomas (n:87) diagnosed in the Pathology Laboratory of Tepecik Training and Research Hospital between 2008 and 2018 were evaluated. We investigated the presence of CRBN protein expression in tumor tissues using IHC staining. The relationship between CRBN expression and various prognostic factors was analyzed. Results: Most of the cases were male (n=179, 64.6%). The mean age of the patients was 60.5± 13.1 years. Overall survival in malignant cases was 30.5±21.8 months, with the shortest survival of 24.7 months in gastric carcinomas. CRBN expression was detected in 92 (33.2%) cases. CRBN positivity rates were highest in neuroendocrine carcinomas (55.6%) and lowest in gastric carcinomas (22.4%). The presence of CRBN expression was statistically significantly different among tumor types (p<0.001). When each group was evaluated separately, a statistically significant relationship was detected between CRBN expression and survival only in gastric carcinomas (p= 0.036). However, contrary to expectations, survival was shorter in patients with CRBN- positive tumors. Conclusion: In cancer treatment, it is very important to identify new targeted treatment options, especially for aggressive tumor types. Since some currently used immunomodulatory drugs target CRBN protein, the use of immunomodulatory drugs may be considered in addition to current therapies in the treatment of solid tumors expressing high levels of CRBN.